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Abstract
Objective—To evaluate in a prospective
study whether patients with polymyalgia
rheumatica (PMR) and patients with
rheumatoid arthritis (RA) with PMR-like
onset show distinctive clinical and labora-
tory features.
Methods—A cohort of 116 consecutive
patients with bilateral girdle pain for at
least one month and raised erythrocyte
sedimentation rate (ESR) was studied and
followed up for 12 months. Laboratory
tests included determination of ESR, IgM
rheumatoid factor, haemoglobin, white
blood cell count, platelet count, percent-
age of CD8 lymphocytes, serum aspartate
aminotransferase, alanine aminotrans-
ferase, alkaline phosphatase, and
glutamyltransferase concentrations.
Results—At first examination, RA was
diagnosed in 22/116 (19%) patients and
PMR in 94 (81%) patients. During the fol-
low up period, 19 additional patients
developed RA, and the diagnosis of PMR
was confirmed in 65 (56%) patients at the
end of the study. Of the clinical and labo-
ratory features, only the presence of
peripheral synovitis could diVerentiate
patients who will develop RA from those
with “true” PMR, but the positive predic-
tive value of this feature was poor.
Conclusion—At present, there are no
clinical or routine laboratory features
allowing early diVerentiation between
PMR and RA with PMR-like onset.
(Ann Rheum Dis 2001;60:1021–1024)
The diVerential diagnosis between polymyalgia
rheumatica (PMR) and elderly onset rheuma-
toid arthritis (RA) can be diYcult because
these conditions may have a similar clinical
presentation. Important features characterising
both diseases are acute involvement of the gir-
dles, severe morning stiVness, raised erythro-
cyte sedimentation rate (ESR), and a good
response to low doses of prednisone.1 2 Elderly
onset RA is characterised by peripheral arthri-
tis, but patients with PMR may also show dis-
tal musculoskeletal manifestations. This fea-
ture occurs in 21–40% of patients with PMR
according to diVerent studies.3–5 Although
some authors have suggested that RA with
PMR-like onset and PMR may be the same
entity,6 7 others have extensively studied how to
diVerentiate these conditions by means of
clinical data, HLA typing, lymphocyte subset-
ting, additional laboratory tests, imaging, or
invasive methods.8–12 The results of these stud-
ies are not conclusive, and the topic is still
debated.
Our work is concerned with a prospective
study of 116 consecutive patients presenting
with PMR-like symptoms in order to evaluate
whether patients with PMR and patients with
RA with PMR-like onset show distinctive clini-
cal and laboratory features.
Patients and methods
We studied prospectively a cohort of 116 con-
secutive patients observed at our institutions.
Inclusion criteria were: (a) age greater than 49
years; (b) bilateral girdle pain (with or without
morning stiVness) for at least one month; (c)
ESR > 40 mm at 1 hour (Westergren). Patients
with a positive ANA test (> 1/160 on Hep2
cells) and/or raised serum creatine kinase con-
centrations were excluded from the study.
Patients already treated with steroids or disease
modifying anti-rheumatic drugs, with evidence
of infectious diseases, neoplasms, or giant cell
arteritis were also excluded.
Clinical assessment was performed by the
same doctor at the first examination, monthly
for the first six months, and every two months
up to one year thereafter. In particular,
systemic signs such as fever, weight loss, head-
ache, and early morning stiVness were re-
corded. Peripheral synovitis and muscle atro-
phy were evaluated clinically. Laboratory tests
were performed at the first visit and every two
months. They included determination of ESR,
IgM rheumatoid factor (RF), haemoglobin,
white blood cell count, platelet count, percent-
age of CD8 lymphocytes (performed in 49
patients), serum aspartate aminotransferase,
Figure 1 Diagnostic tree of the course of the disease in patients presenting with
polymyalgia rheumatica (PMR)-like features, during 12 months of follow up. RA,
Rheumatoid arthritis; PMR, polymyalgia, rheumatica. Three patients with cancer and three
with giant cell arteritis.
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alanine aminotransferase, alkaline phos-
phatase, and glutamyltransferase concentra-
tions. RA was diagnosed according to the 1987
ACR (formerly ARA) criteria,13 and PMR was
diagnosed as described by Jones and Hazle-
man.14 An x ray examination of hands and
wrists was performed at the first examination,
after six months, and at the end of the study;
clinical and laboratory criteria were checked at
each examination. The study was discontinued
after 12 months. After the first examination,
patients not fulfilling the ACR criteria for RA
were treated with prednisone alone at an initial
dose of 17.5 mg/day. Prednisone was than
tapered to achieve a maintenance dose of 5
mg/day after eight months. Patients with a
diagnosis of RA were treated and followed
according to standard clinical guidelines and
were not considered for final evaluation.
STATISTICAL ANALYSIS
DiVerences between groups were evaluated
using the non-parametric Mann-Whitney test
for continuous variables and the ÷2 test with
continuity correction for categorical variables.
As multiple comparisons were performed, the
Bonferroni adjustment was applied.15 The per-
centage of patients with persistent PMR or who
developed RA during the follow up was calcu-
lated by the log rank test.16
Results
DIAGNOSIS AND FOLLOW UP
At first examination, a diagnosis of RA was
made in 22/116 (19%) patients, who were
excluded from further study. An initial diagno-
sis of PMR was made in the remaining 94/116
(81%) patients who were followed up for 12
months. During this period, three patients
developed a malignancy (gastric cancer, lung
cancer, lymphoma), three developed clinical
and histological signs of giant cell arteritis, and
four were lost to follow up (fig 1). A total of 84
patients was therefore evaluable after 12
months. A good initial response to prednisone
was seen in all these patients despite occasional
flare ups of the symptoms or the involvement of
additional joints in 25 patients. In 19 of these
25 patients, the diagnosis was changed to RA
because the ACR criteria were now fulfilled. In
the remaining six patients with flare ups, the
diagnosis of PMR was confirmed. In this last
group, an increase in prednisone dose up to the
last previous dose led to a complete clinical and
serological recovery. Therefore the final diag-
nosis was RA in 41 patients (22 at first exami-
nation and 19 during the follow up) and PMR
in 65 patients. Figure 2 shows the curve of the
patients maintaining their diagnosis of PMR
over the follow up period and the time when
the diagnosis of RA was made.
PRESENTING FEATURES
Patients with RA diagnosed at the first exami-
nation (22 patients) were not considered for
the evaluation of presenting features. As
depicted in fig 1, during the 12 months of fol-
low up, 10 of 94 patients with an initial diagno-
sis of PMR were withdrawn from the study
(four lost of to follow up and six for other dis-
eases). Of the remaining 84 patients, 19 (23%)
developed RA during the follow up, and 65
(77%) maintained the diagnosis of PMR.
These two groups were similar for age, sex,
and inflammation indices (tables 1 and 2).
Weight loss was more often observed in
patients with a final diagnosis of PMR, whereas
proximal muscle atrophy and peripheral syno-
vitis were more common in patients with RA.
However, after correction for multiple com-
parisons, only the presence of peripheral
arthritis remained significantly diVerent be-
tween the two groups. Arthritis was present in
17/65 (26%) patients with PMR and in 15/19
(79%) patients with RA (adjusted p<0.002)
(table 1). However, this clinical feature has a
poor positive predictive value, as only 15 out of
32 (47%) patients with peripheral arthritis
developed RA. Of the laboratory tests, only
IgM RF positivity was more common in
patients with RA than in patients with PMR,
but this diVerence disappeared after Bonferro-
ni’s correction; RF titre was also similar in the
two groups of patients.
Figure 2 Kaplan-Meier curve showing the percentage of
patients presenting with polymyalgia rheumatica
(PMR)-like features (n = 116) whose diagnosis remained
PMR during a one year follow up. *Number of patients
with a new diagnosis of rheumatoid arthritis.
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Table 1 Main clinical features in the two groups of
patients, divided according to the final diagnosis
PMR*
(n=65)
RA*
(n=19) p Value
Male/female 20/45 7/12 NS*
Mean age (years) 70.1 68.8 NS
Fever 23 4 NS
Weight loss 25 2 0.02
Morning stiVness >1 hour 47 15 NS
Proximal muscular atrophy 1 3 0.03
Headache 15 4 NS
Peripheral synovitis 17 15 0.0001†
*PMR = Polymyalgia rheumatica; RA = rheumatoid arthritis;
NS = not significant.
†p<0.002 after Bonferroni’s correction.
Table 2 Main radiological and laboratory features in the two groups of patients, divided
according to the final diagnosis
PMR* (n=65) RA* (n=19) p Value
Erosions (plain standard radiograph) 0 0 NS*
ESR* (mm/1st hour) (mean) 74.9 83.6 NS
Rheumatoid factor (No of positive patients) 8 7 0.03
Rheumatoid factor (titre) 92 (32–424) 98 (40–820) NS
Alkaline phosphatase and/or ãGT* increase 16 1 0.1
AST* and/or ALT* increase 2 1 NS
WBC* >10 × 109/l 15 2 NS
PLT* >450 × 109/l 11 1 NS
Haemoglobin <105 g/l 10 1 NS
% CD8 (mean (SD))† 28 (7) 31 (9) NS
*PMR = Polymyalgia rheumatica; RA = rheumatoid arthritis; NS = not significant; ESR = eryth-
rocyte sedimentation rate; GT = glutamyltransferase; AST = aspartate aminotransferase; ALT =
alanine aminotransferase; WBC = white blood count; PLT = platelet count.
†Limited to 49 patients (39 PMR and 10 RA).
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No significant diVerences were observed for
the other laboratory variables including CD8
lymphocyte percentage, which was evaluated in
a subset of 49 patients (39 PMR and 10 RA).
Discussion
Since Bagratuni’s first description of PMR,17
similarities between this condition and RA
have been described. Several studies have
shown that RA can be diagnosed in 6–17% of
patients initially classified as PMR and fol-
lowed up for three to five years.1 4 18 19 On the
other hand, it is well known that a usually
seronegative subset of elderly onset RA may
show a PMR-like onset with prevalent involve-
ment of the girdles, high ESR values, and good
response to low dose steroid treatment.1 2 20 21
Moreover, inflammatory involvement of pe-
ripheral joints and/or tenosynovial structures is
described in a high proportion of patients with
PMR.5 22 The demonstration that PMR is a
synovitis by arthroscopic biopsy and ultra-
sonography of the shoulder joints may provide
an explanation for such observations.12 23–25
However, the similarity and possible overlap in
the presenting features of PMR compared with
elderly onset RA has been the subject of some
debate.
In our study we prospectively examined
patients presenting with PMR-like onset. We
noted that in 22 of these patients (19%), a
diagnosis of RA was possible at the first exami-
nation, and in an additional 19 patients a diag-
nosis of RA was confirmed over a 12 month
follow up. As a result, of 116 patients examined
because of PMR-like symptoms at onset, 41
(35%) had RA or developed it within one year.
The diagnosis of PMR was confirmed in 65
(56%) cases. In contrast, Bahlas and coworkers
found RA subsequent to the diagnosis of PMR
in only 17/149 patients (11%).4 This discrep-
ancy may be due to the retrospective design of
their study. In addition, these authors found
cancer in four (2.6%) of their patients, a low
frequency confirmed in our study (3/116;
2.6%).
Whether PMR and RA with a PMR-like
onset are the same disease, or if some
diVerences exist that could be helpful in the
diVerential diagnosis is still a matter of debate.
To investigate this topic further, we compared
among patients satisfying at presentation the
commonly used criteria for the diagnosis of
PMR14 those with persistent PMR and those in
whom RA developed during the follow up. The
only significant diVerence between the two
groups was the more common involvement of
peripheral joints in patients with RA. However,
this diVerence seems to be of poor clinical
value, because peripheral arthritis was present
in 15/19 (79%) patients with RA but also in
17/65 (26%) patients with PMR. The last
figure is very similar to that recently reported
by Salvarani and coworkers for 177 Italian
patients with PMR5 and Gran and Myklebust
in a prospective study from South Norway.22 As
a result, less than half of the patients with gir-
dle involvement and peripheral synovitis can be
expected to develop RA after an initial diagno-
sis of PMR. The importance of a low percent-
age of CD8 T lymphocyte before treatment in
distinguishing PMR and RA at disease onset
has been reported by Corrigal and coworkers.10
Our data also showed a lower CD8 cell count
in patients with PMR in comparison with
patients with RA. The usefulness of this test for
diVerential diagnosis cannot be confirmed
because the values obtained in the two groups
of patients were largely overlapping. Geo-
graphical diVerences may partially account for
this diVerence because our data are very similar
to those reported by Boiardi and coworkers for
patients with PMR and RA from another loca-
tion in Northern Italy.26
As expected, RF positivity was more com-
mon in patients with RA than in patients with
PMR. However, this diVerence was not statisti-
cally significant. The high prevalence of RF
positivity in our patients with either PMR or
RA with PMR-like onset, usually described as
seronegative diseases in other series, is surpris-
ing. Epidemiological studies on RF prevalence
in the Italian population are lacking. However,
environmental and/or genetic factors leading to
a high rate of RF positivity in the Italian popu-
lation exist. For example, hepatitis C virus
infection, with or without mixed cryoglobuli-
naemia, is a potent inducer of RF production
by plasma cells.27 The prevalence of antibodies
to hepatitis C virus in the Italian general popu-
lation is between 3.2% and 12.6%,28 and can
reach 40% among elderly subjects of certain
Italian regions.29
The evaluation of new diagnostic tools such
as antibodies against putatively citrullinated
antigens (SA filaggrin, CCP) could be of inter-
est in this subset of patients, even though their
predictive value in seronegative RA appears to
be low30; studies on this topic are warranted.
Several other clinical and laboratory vari-
ables have been suggested as useful in the
diVerential diagnosis between PMR and RA
with PMR-like onset. These include scinti-
graphic evaluation of the shoulder,8 thrombo-
cytosis,31 serum cytidine deaminase,11 and anti-
bodies to laminin B2 protein.32 However, all
these observations need further confirmation
and none of them is usually used in clinical
practice.
On the other hand, HLA typing does not
seem to allow early diVerentiation between RA
and PMR.33
We are aware that a one year study does not
allow us to draw definite conclusions. Notwith-
standing, the data from this prospective study
appear of some interest, in that about 35% of
patients presenting with symptoms resembling
PMR actually have or will develop RA during
12 months of follow up. More interestingly,
when considering only patients with an initial
diagnosis of PMR, more than 20% will develop
overt RA during the follow up. At present,
there are no clinical or routine laboratory
features allowing early diVerentiation between
these patients and patients with persisting
PMR.
DiVerentiation between PMR and RA with PMR-like onset 1023
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